Cas No.116112-80-2 4-[(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)oxy]-Butanoic acid

Glycosylation modification is commonly used in drug development to enhance the water solubility, metabolic stability, and biological targeting of drugs. The galactose group of this compound can be introduced into drug molecules to improve drug performance through glycosylation modification, especially in the development of anticancer, antiviral, and antibacterial drugs, which have important applications. The galactose group can bind to specific receptors, especially sugar receptors in the liver (such as galactose receptors enriched on the surface of liver cells). Therefore, this compound can be used to design targeted delivery systems for delivering drugs or other molecules to specific tissues or cells, such as the liver. This delivery system has potential in the treatment of liver diseases and liver targeted gene therapy.